Response
Chest
.
2018 Nov;154(5):1262-1264.
doi: 10.1016/j.chest.2018.07.033.
Authors
Robert P Frantz
1
,
Carol Zhao
2
,
Harrison W Farber
3
,
David B Badesch
4
,
C Greg Elliott
5
,
Adaani E Frost
6
,
Michael D McGoon
7
,
David R Mink
8
,
Mona Selej
2
,
Raymond L Benza
9
Affiliations
1
Mayo Clinic, Rochester, MN. Electronic address: frantz.robert@mayo.edu.
2
Actelion Pharmaceuticals US, Inc. South, San Francisco, CA.
3
Pulmonary Center, Boston University School of Medicine, Boston, MA.
4
University of Colorado, Denver, CO.
5
Intermountain Medical Center and the University of Utah School of Medicine, Salt Lake City, UT.
6
Houston Methodist Lung Cancer, Weill Cornell Medical College, Houston, TX.
7
Mayo Clinic, Rochester, MN.
8
former employee of ICON Clinical Research.
9
Allegheny General Hospital, Pittsburgh, PA.
PMID:
30409362
DOI:
10.1016/j.chest.2018.07.033
No abstract available
Publication types
Letter
Comment
MeSH terms
Familial Primary Pulmonary Hypertension
Humans
Natriuretic Peptide, Brain*
Registries
Substances
Natriuretic Peptide, Brain